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Abstract  
Invariant natural killer T (iNKT) cells are innate-like lymphocytes that respond to 
glycolipids with rapid cytokine release, including IFN-γ, IL-4 or IL-17, thus recapitulating 
many features of T-helper (Th) responses. Furthermore, the host laboratory recently 
showed that iNKT cells can induce de novo expression of Foxp3 in presence of TGF-β, 
thereby adopting a regulatory phenotype similar to Treg cells. 
Specific Th-like cytokine patterns have been associated to distinct iNKT-cell 
NK1.1/CD4 subsets. We investigated the plasticity of these four subpopulations in 
response to the same stimuli driving the polarization of conventional CD4 T cells 
towards a Treg, “Th9” or Th17-like phenotype in vitro. Polarization was achieved within 
all iNKT-cell subsets, although with different efficiencies. Importantly, NK1.1/CD4 were 
down-modulated, suggesting their expression probably define functional states rather 
than fixed lineages. 
Using an allergic airways disease model where iNKT cells play a pathogenic role, we 
showed that anti-CD4 monoclonal antibody (MAb) treatment decreased iNKT-cell 
infiltrates in the airways and modified iNKT-cell phenotype in the draining lymph nodes, 
which correlated with disease prevention. 
Our results also show that, in a model of experimental autoimmune encephalomyelitis 
where a protective role is attributed to iNKT cells, anti-CD4 MAb treatment, as well as 
α-GalCer (a specific iNKT agonist) administration can prevent the disease. This 
correlated with increased iNKT-cell content in cervical LNs and spleen compared to 
sick mice and, more importantly, with higher numbers of Foxp3+ iNKT cells. 
Collectively, our results reveal that all NK1.1/CD4 iNKT-cell subsets share a similar 
plasticity in response to environmental stimuli, thus challenging the general assumption 
that cytokine expression is restricted to certain iNKT subpopulations. Finally, we also 
show that iNKT cells can be subject to immunomodulation protocols that prevent 
diseases, which renders this population a new potential target for pharmacological 
intervention aiming to control immune mediated disorders.  
 
 
Key-words 
Invariant Natural Killer T cells; In vitro polarization; TGF-β;  Allergic Airways disease; 
Encephalomyelitis Autoimmune Experimental; Regulatory T cells; T helper subtypes;  
Tolerance 
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Resumo  
 
As células T “natural killer” invariantes (iNKT) constituem uma população 
heterogénea de linfócitos capaz de expressar receptores típicos de células NK (como 
NKG2D e NK1.1 - CD161 em humanos) e de linfócitos T convencionais (como CD3, 
CD4, CD8 ou TCR αβ). Estas células desenvolvem-se no timo e reconhecem 
glicolípidos apresentados por CD1d, uma molécula não clássica do complexo principal 
de histocompatibilidade (MHC). Apesar de representarem uma pequena população 
dentro do sistema imunitário (menos de 1% no sangue periférico humano), têm sido 
implicadas na modulação de diferentes patologias, incluindo na asma alérgica e na 
esclerose múltipla. A sua activação leva à rápida secreção de citocinas características 
de respostas Th1, Th2, “Th9” ou Th17. Estes tipos de resposta têm sido associados a 
diferentes linhagens de linfócitos iNKT, identificadas de acordo com a expressão de 
NK1.1 e do co-receptor CD4: respostas do tipo Th1 têm sido associadas a 
subpopulações CD4-, respostas do tipo Th2 atribuem-se principalmente a 
subpopulações CD4+ e, mais recentemente, dois estudos diferentes restringiram a 
secreção de IL-17 às subpopulações NK1.1-. Para além disso, resultados obtidos no 
nosso laboratório demonstram que, na presença de TGF-β, é possível induzir um 
fenótipo T regulador (Treg) associado à expressão do factor de transcrição Foxp3, 
tanto em células iNKT de ratinho, como humanas. Note-se que todas as células iNKT 
em que é induzida a expressão de Foxp3 perdem NK1.1 na sua superfície, embora 
possam expressar ou não o co-receptor CD4. 
Para avaliar a plasticidade de cada uma das quatro subpopulações NK1.1/CD4 de 
células iNKT em resposta a diferentes estímulos, estas células foram isoladas de 
baços de ratinhos C57BL/6, as diferentes subpopulações identificadas com base na 
expressão de NK1.1 e CD4 e, então, separadas por citometria de fluxo. Após 3 a 5 
dias de cultura nas condições usadas para induzir a expresão de Foxp3 ou IL-17 em 
células T CD4 convencionais, verificou-se que todas as subpopulações NK1.1/CD4 de 
células iNKT têm a capacidade de induzir a expressão destes genes. A expressão dos 
mesmos, no entanto, não foi detectável por citometria de fluxo quando as células 
foram analisadas ex vivo, antes da cultura. Curiosamente, foi detectada nas culturas  
que conduzem à indução de Foxp3 a expressão de elevados níveis IL-9. Sabe-se que 
a polarização para um fenótipo do tipo “Th9” é dependente de TGF-β e IL-4. Contudo, 
esta última citocina não constitui um componente do cocktail de polarização 
adicionado às culturas de indução de Foxp3. No entanto, as células iNKT são capazes 
de secretar IL-4 após activação, tendo a sua presença sido detectada por ELISA nos 
sobrenadantes das culturas. Esta observação sugere que as células iNKT em cultura, 
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ao serem estimuladas secretam IL-4 que, em sinergia com o TGF-β adicionado 
exogenamente, actua de forma autócrina sobre as células iNKT levando à indução da 
expressão de IL-9. Esta hipótese foi confirmada num ensaio em que diferentes 
concentrações de anticorpo neutralizante contra IL-4 foram adicionadas às culturas, o 
que não afectou a expressão de Foxp3, mas diminuíu de forma significativa a 
secreção de IL-9. Note-se que, no entanto, as eficiências de polarização para os 
diferentes fenótipos foram diferentes nas quatro subpopulações de células iNKT. A 
expressão máxima de Foxp3 foi observada na subpopulação NK1.1-CD4- (41%), 
sendo as restantes semelhantes entre si (20%). A expressão de IL-9 intracelular, por 
sua vez, variou entre os 5 e os 15% em todas as subpopulações, parecendo haver 
uma tendência para uma expressão mais elevada nas subpopulações NK1.1+CD4+ e 
NK1.1+CD4-. A expressão de IL-17 foi máxima nas subpopulações NK1.1-CD4+ e 
NK.1+CD4- (aproximadamente 30%) não ultrapassando os 10% nas restantes 
subpopulações. De notar que as quantidades de IL-17 secretadas por estas 
subpopulações são cerca de oito vezes superiores às produzidas por células T CD4 
convencionais polarizadas nas mesmas condições. Apesar de, no caso da indução de 
IL-17, os resultados obtidos não serem suficientes para excluir expansão de células IL-
17+ pré-existentes, estes indicam porém que a expressão de IL-17, bem como de IL-9 
ou Foxp3, não é restrita a uma subpopulação específica, como previamente sugerido. 
Em todas as condições e subpopulações de células iNKT houve uma perda da 
expressão de NK1.1 e/ou CD4 após polarização, o que sugere que estas moléculas 
não definem linhagens dentro da população de linfócitos iNKT, reflectindo 
provavelmente um estado funcional. 
A elevada plasticidade apresentada pelas células iNKT e a capacidade de apresentar 
um fenótipo regulador sugere a utilidade da sua manipulação para fins terapêuticos. 
Para testar esta hipótese, tiramos partido de dois modelos animais de resposta do tipo 
Th2 (asma alérgica) ou Th17 (esclerose múltipla), nos quais se sugere, 
respectivamente, um papel de agravamento ou protecção da doença por parte das 
células iNKT. Estudos efectuados pelo nosso grupo demonstraram que em ambas as 
patologias é possível reprogramar o sistema imunitário de modo a induzir tolerância 
através da administração de um anticorpo monoclonal anti-CD4 não depletante. Uma 
vez que as células iNKT podem expressar este co-receptor, colocámos a hipótese de 
que o estado de tolerância induzido pela administração do anticorpo pode dever-se 
também a alterações induzidas nesta população, reflectindo-se numa alteração nos 
números, fenótipo ou função das células iNKT. 
No modelo de asma alérgica induzida mediante a administração intra-nasal de 
ovalbumina, o grupo experimental de ratinhos em que a doença foi prevenida com o 
anticorpo anti-CD4 apresentou uma diminuição nos infiltrados de células iNKT nos 
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lavados bronco-alveolares e nos pulmões, mas não nos gânglios linfáticos do 
mediastino. Apesar de os números de células iNKT nos gânglios drenantes não serem 
significativamente alterados, observámos alterações no seu fenótipo: a expressão de 
CD62L, CD103, e CD4 foi diminuída. Assim, para investigar se as mesmas alterações 
ocorrem na presença de um alergéneo mais fisiológico, a patologia foi induzida com 
ácaros. O mesmo protocolo de tolerância com anti-CD4 revelou-se capaz de prevenir 
a doença, levando a uma diminuição da infiltração de células iNKT nas vias aéreas. 
No modelo de esclerose múltipla, observámos que os números de células iNKT no 
baço e gânglios linfáticos cervicais de ratinhos doentes eram inferiores aos do grupo 
controlo saudável, sendo a maioria destas células CD4-. O tratamento com o anticorpo 
monoclonal anti-CD4 teve um elevado sucesso na prevenção das manifestações 
clínicas da doença, impedindo a infiltração linfocitária do sistema nervoso central e 
levando a um aumento das células iNKT nos gânglios linfáticos cervicais e no baço, 
atingindo níveis semelhantes aos dos controlos saudáveis. De salientar que, neste 
modelo, detectámos pela primeira vez a expressão de Foxp3 nas células iNKT in vivo, 
estando o número destas células aumentado em animais que receberam o tratamento 
com o anticorpo. 
Em conclusão, os resultados obtidos nos modelos de asma alérgica e esclerose 
múltipla sugerem que o tratamento com anticorpo monoclonal específico do co-
receptor CD4 tem também impacto na população de células iNKT. Ainda que a acção 
deste anticorpo possa ser directa, dado que muitas células iNKT expressam CD4, não 
é possível excluir a possibilidade de que a acção seja indirecta, através linfócitos T 
CD4 convencionais. 
Considera-se que a activação de células iNKT no modelo de esclerose múltipla 
contribui para a prevenção dos sintomas, estando associada à inibição da proliferação 
de células T convencionais agressivas do tipo Th17. Contudo, a relação desta 
protecção com um fenótipo regulador associado à expressão de Foxp3 nunca tinha 
sido investigada. Para testar esta hipótese, num grupo experimental de ratinhos em 
que a doença foi induzida, procedeu-se à activação in vivo das células iNKT com o 
ligando específico α-GalCer, em paralelo com a imunização. O estado de tolerância 
induzido por este protocolo foi semelhante ao induzido pelo anticorpo monoclonal anti-
CD4, levando não só ao aumento do número de células iNKT nos gânglios linfáticos 
drenantes e no baço, mas principalmente a um aumento de células iNKT reguladoras 
que expressam Foxp3. Estudos adicionais são necessários para compreender os 
mecanismos subjacentes a este fenómeno. 
A capacidade das células iNKT de mimetizar diferentes subtipos de células T CD4,  
nomeadamente a capacidade de adquirir um fenótipo regulador, associada à rápida e 
elevada produção de factores solúveis, sugere a possibilidade de utilização de terapias 
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dirigidas a esta população de linfócitos. Observámos que é possível expandir estas 
células em resposta a α-GalCer, o que sugere que é possível a sua utilização em 
terapias autólogas. A compreensão do grau de implicação das células iNKT em 
diferentes patologias humanas é importante para seleccionar as melhores abordagens 
de intervenção terapêutica. Em suma, os nossos estudos sugerem que a população 
iNKT pode ser um alvo promissor de imunoterapia. 
 
 
Palavras Chave 
Células T “natural killer” invariantes; Polarização in vitro; TGF-β; Asma Alérgica; 
Encefomielite autoimune experimental; Células T reguladoras; subtipos T helper;  
Tolerância. 
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Introduction 
 
 
The immune System 
 
A huge variety of pathogenic microbes, such as viruses, bacteria, fungi, protozoa, etc. 
have the ability to invade host organisms, causing disease or even leading to death. 
Such threats acted as selective pressures among evolution driving species to evolve 
multiple defensive mechanisms generally known as the immune system. This 
protective approach not only protects organisms from infectious agents, but also 
monitors altered cells, thus preventing tumor development within the host.  
The immune response starts with the recognition of an antigen, which triggers a 
series of events involving the cooperation of soluble mediators and immune cells that 
ultimately lead to its neutralization or elimination [1]. In vertebrates, immune responses 
fall into two categories: innate immune responses and adaptive immune responses. 
Innate immunity is associated with the recognition of a broad spectrum of conserved 
structures among pathogens leading to a prompt response that does not change upon 
repeated exposure to the same agent. On the other hand, adaptive immune responses 
are highly specific, recognizing specific structures of pathogens and allowing 
immunological memory to emerge after the first encounter with an antigen [2]. 
Lymphocytes play a major role in adaptive immunity. They can be classified in two 
categories: B cells, which bear a B-cell receptor (BCR) and are responsible for 
antibody secretion; and T cells, which express an αβ/γδ T-cell receptor (TCR) and are 
responsible for cell-mediated immunity. αβ T cells, can further be divided according to 
the type of co-receptor they express: CD8 or CD4. CD8 T cells recognize antigens 
presented by the major histocompatibility complex (MHC) class I on the surface of any 
nucleated cell to which they can directly bind, inducing programmed cell-death of target 
cells through a variety of cytotoxic mechanisms. CD4 T cells are activated by peptides 
presented by MHC class II molecules on the surface of antigen presenting cells 
(APCs), providing cellular interactions with other lymphocytes important for the 
differentiation of their effector functions, as well as secreting soluble factors that 
mediate the recruitment, proliferation and differentiation of other cells involved in the 
immune response [3]. Since the cellular and soluble signals provided by CD4 T cells 
are vital to help other lymphocytes to accomplish their functional maturation, CD4 T 
cells were also designated as “helper” T cells (Th). 
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CD4 T-cell responses  
 
Activation of naïve T cells following the encounter of a specific antigen induces their 
proliferation and differentiation of effector functions. The nature of such effector 
functions is used to classify the distinct CD4 T-helper subsets, which differentiate in 
response to different cytokines and are associated to characteristic transcription factors 
[4] (Fig 1). Type-1 T-helper (Th1) cells express the transcription factor T-bet and 
secrete IFN-γ and tumor necrosis factor (TNF) in response to IL-12. These effector 
cytokines play a major role in immune responses against intracellular pathogens and 
mediate tissue inflammation. Th2 cells are associated to GATA-3 expression, produce 
IL-4, IL-5 and IL-13, and differentiate in response to IL-4. These cells are involved in 
responses to extracellular pathogens, as well as in allergic reactions. Described more 
recently, Th17 cells require the transcription factor RORγt to differentiate and secrete 
IL-17A and IL-17F, being involved in  the development of autoimmune and allergic 
diseases and host defense against a group of extracellular bacteria and fungi [5]. 
Another distinct population of helper–effector T cells that promotes tissue inflammation 
and lacks suppressive function, was recently identified as IL-9+IL-10+[6, 7]. However 
the transcription factor that associated to this “Th9” subtype remains yet to be 
identified. 
To control exacerbated immune responses, which can cause severe damage to the 
host organism, several regulatory mechanisms have evolved. CD4+CD25+Foxp3+ 
regulatory T cells (Treg) and IL-10-producing type 1 regulatory T cells (Tr1) play a 
major role in this regulation. Naturally occurring Treg express the transcription factor 
Foxp3 and are generated in the thymus[2, 8]. More recently, evidence came up that 
Treg cells could also be generated in the periphery upon suboptimal activation of naïve 
T cells, depending on the balance of transforming growth factor β (TGF-β) and other 
soluble factors  [9, 10].  
 
 
TGF-β as a master regulator of Th differentiation 
 
TGF-β, which was first discovered as a growth factor for non-immune cells, is now 
consensually recognized as an important factor controlling immune responses. TGF-β 
is a pleiotropic cytokine  that prevents macrophage activation, dendritic cell (DC) 
maturation, B-cell antibody production and Th1 or Th2 differentiation[11]. As mentioned 
above, TGF-β was shown to be required for the generation of Treg cells in the 
periphery (also called acquired or induced Tregs) in both mice and humans. Some 
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studies show that TGF-β increases the activation threshold of naïve T cells through the 
Ca2+-calcineurin cascade, thus contributing to a suboptimal activation state that 
induces a genetic program leading to the upregulation of Foxp3 [12]. 
Interestingly, in vitro studies have shown that in presence of pro-inflammatory 
cytokines, TGF-β-dependent induction of Foxp3 is abrogated [6, 7]. For instance: in the 
presence of IL-4, the differentiation program of naïve CD4 T cells is driven towards a 
“Th9” phenotype characterized by IL-9 and IL-10 expression in both mice [6, 7] and 
humans [13]. In the presence of IL-6 and IL-1β, CD4 T cells are induced to express IL-
17 [14-16]. 
 
Fig. 1 Naive CD4+ T cells (Th0) can differentiate to different subtypes. The signal 
generated by TCR engagement with the antigen presenting cells (APC) and the cytokine milieu 
that in the surrounding environment induce the expression of the transcription factors and 
signature cytokines. These are responsible for the different functions of each subtype.  
 
 
 
NKT cells 
 
NKT cells, first described in the late 1980s, represent a distinct subset of T 
lymphocytes with regulatory capacity that recognizes glycolipid antigens presented by 
the non-classical MHC class I-like molecule CD1d[17]. The key factors leading to NKT 
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development and activation have been intensively studied[17-19]. Despite some 
endogenous antigens, such as isoglobotrihexosylceramide (iGb3), have already been 
identified, the existence of a ligand in the thymus responsible for their development is 
still a matter of controversy [17, 18, 20].  
Like conventional T cells, NKT cells express an αβ TCR and the CD3-signalling 
complex. They also express receptors from the NK lineage, such as NKG2D and 
NK1.1 (NKR-P1C and CD161 in humans) [17]. More recently PLZF was identified as 
the specific transcription factor of the NKT lineage [21]. Although recognition of CD1d 
molecules by NKT cells’ TCR does not require co-receptors, such as CD4 or CD8, 
which are essential for successful activation of conventional T cells, NKT cells can 
express these co-receptors[17]. In mice, most NKT cells are CD4+, and a smaller 
subset lacks both CD4 and CD8 expression (referred as double negative or DN). In 
contrast,  human NKT cells can be CD4+, CD8+ or DN [17, 19, 22, 23]. A recent report, 
where iNKT-cell enriched mice were used, suggests that CD8+ iNKT cells might also 
exist in mice, although in extremely reduced frequency, thus preventing its detection by 
flow cytometry  [24].  
Type I NKT cells (also known as classical or invariant NKT (iNKT) cells) have a semi-
invariant TCR comprising an invariant α-chain (Vα14-Jα18 in mice, Vα24-Jα18 in 
humans) and a restricted TCR-β chain repertoire (Vβ8.2, Vβ7, Vβ2 in mice, Vβ11 in 
humans), which recognize glycolipids presented by CD1d. These cells recognize the 
synthetic glycosphingolipid α-galactosylceramide (α-GalCer), isolated from the marine 
sponge Agelas mauritianus. This ligand, and its analogs are now commonly used to 
unambiguously identify iNKT cells through the binding to fluorescently-labeled CD1d 
dimmers, tetramers or pentamers [25]. 
Type II NKT cells are also CD1d dependent but express a broader range of Vα 
chains. Much less is known about this subset due to the lack of specific reagents for 
their unambiguous identification [19].  
Although iNKT-cell lineage can be distinguished from conventional T lymphocytes at 
molecular level through the expression of PLZF, no commercial antibody is yet 
available for this transcription factor [21]. Many studies done so far rely on the 
expression of NK markers, such as NK1.1, and TCR to identify iNKT cells. However 
this approach is not formally correct for several reasons. First, activated T cells can up 
regulate NK receptors such NK1.1 and, thus, be mistakenly identified as iNKT cells. 
Secondly, not all iNKT-cell subpopulations express NK1.1 thus incurring the risk of 
being considered conventional CD4+ T cells. For instance, activated iNKT cells tend to 
downmodulate NK1.1. Finally, some mouse strains lack the expression of several NK 
markers, such as NK1.1 in the Balb/c strain [26].  
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In spite of many of the molecules expressed by iNKT cells being shared with other 
cell types, they have unique identity following a defined thymic selection process not 
shared with conventional T cells. Given the overlap in terms of markers, the best 
available strategy for unambiguous identification of iNKT cells still relies on their 
specificity to glycolipids presented in the context of CD1d. 
 
 
iNKT cell function 
 
Although iNKT represent less than 1% of human peripheral blood mononuclear cells 
(PBMC) or splenic cells in mice, after activation by CD1d-bound antigens, they respond 
within hours in an “innate-like” way by producing massive amounts of IL-4 and IFN-γ 
[26]. Such rapid response is explained by the presence in the cytosol of many pre-
synthesized mRNA molecules coding for those cytokines, which were produced prior to 
antigen stimulation [27].  
Importantly, iNKT cells share with conventional T cells several characteristics, such 
as the expression of CD8, CD4 and an αβ TCR as mentioned above. In addition, they 
are capable of secrete soluble factors, like chemokines and cytokines, characteristic of 
different T helper subsets [22, 28-33], including IFN-γ, IL-4 and IL-17. These molecules 
are currently believed to be associated to fixed lineages within iNKT cells [19, 27, 32, 
34]. In particular, Th2-like phenotypes are mainly attributed to CD4+ iNKT cells, while 
Th1 are associated to CD4- [31, 34, 35]. In addition, IL-17 expression by iNKT cells was 
first considered to be restricted to NK1.1-CD4-compartment [31, 32]. 
However, two CD4-effector type cells have no known parallel in iNKT cells. The first 
is the “Th9” phenotype, despite IL-9 secretion by these lymphocytes has already been 
demonstrated [32]; and the second is a regulatory phenotype associated to Foxp3 
expression.  
Taking advantage of several in vitro culture systems, the host team has observed it is 
possible to convert freshly isolated murine and human iNKT cells to different functional 
states. This strategy has been routinely used in the laboratory in the last years to study 
the plasticity of iNKT cells and understand its impact on the orchestration of immune 
responses. 
 
 
iNKT cells in immune mediated diseases 
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iNKT cells have been shown to play a  role in a broad range of responses, including 
graft rejection [36], allergy [37, 38], autoimmunity [39, 40] and other inflammatory 
pathologies[17, 41], of which allergic asthma and multiple sclerosis have been the most 
extensively studied. 
 
iNKT cells in allergic asthma 
Allergic asthma is characterized by chronic airways inflammation, with the 
participation of basophils, mast cells,  eosinophils, IgE-producing B cells, CD4+T cells 
and iNKT cells [42, 43]. These lymphocytes secrete Th2-type cytokines such as IL-4, 
IL-5 and IL-13, whose role in asthma is well established [44]: IL-4 promotes isotype 
switch to IgE; IL-5 recruits eosinophils to the lungs and IL-13 induces goblet cell 
hyperplasia playing an important role in mucous secretion, airways hypereactivity 
(AHR) and tissue remodeling. These events, result in intermittent airway obstruction, 
which is responsible for asthma’s typical episodes of breathlessness and wheezing 
[44]. 
Th2-type cytokine production has been generally attributed to conventional CD4+ T 
cells. However, recent studies using mice deficient in iNKT cells, which fail to develop 
allergen-induced airways disease (AAD) and AHR, have convincingly demonstrated 
that adoptive transfer of wild-type iNKT cells could restore the capacity to induce the 
disease [45] and that such ability was dependent of Th2-type cytokines, as similar 
transfer experiments with iNKT cells from mice deficient in IL-5 or IL-13 failed to rescue 
the susceptibility to develop AHR. Furthermore, stimulation of pulmonary iNKT cells 
induced per se AHR in mice, even in the absence of B cells or conventional CD4 T 
cells [37].  
NKT cells have been implicated in the pathology of allergic asthma in humans as well 
[35], although in a more controversial way. Indeed the presence of a relative high 
frequency (up to 80%) iNKT cells was described in the airways of patients with severe 
allergic asthma [35]. However these observations were not in agreement with a second 
report where less severe cases were studied [46]. Moreover, the data presented by 
these authors suggests that iNKT cells might have been mistakenly identified. 
Therefore, further research in this area is required. 
 
iNKT cells in multiple sclerosis 
Multiple sclerosis (MS) is an immune-mediated inflammatory disease caused by 
infiltration of the central nervous system (CNS) by auto reactive T cells recognizing 
myelin antigens. These effector lymphocytes elicit the recruitment of additional 
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inflammatory cells into the CNS, ultimately leading to axonal damage and glial scar 
formation. The disease can manifest in different forms, including relapsing-remitting, 
chronic progressive and relatively benign phenotypes[47].  
Contrary to allergic asthma, which relies on a Th2-type response, the key pathogenic 
players in multiple sclerosis were shown to be T cells producing IFN-γ and IL-17 [48]. 
This is supported by several observations: (1) the adoptive transfer of Th17 cells, but 
not Th1 cells, induces experimental autoimmune encephalomyelitis (EAE; a mouse 
model for multiple sclerosis) in mice [49]; (2) neutralizing antibodies for IL-17 can 
ameliorate EAE [50]; (3) and antibodies against IL-23 – a cytokine required for Th17 
response - can prevent EAE induction and reverse established disease[51]. While the 
number and function of CD4+CD25+ regulatory cells appear reduced in multiple 
sclerosis patients[52], correlating to the relapse remit progression of the disease in 
EAE models, activation and/or enrichment of iNKT cells in EAE have been reported to 
correlate with disease attenuation and protection [53-55]. The beneficial role of iNKT 
cells was suggested to be due to their increased cytotoxic potential towards the 
pathogenic cells and to the prevention of Th17 differentiation [56]. However a direct 
and more extensive study of the phenotype and function of CNS-infiltrating iNKT cells 
is lacking to confirm those results and to accurately describe the contribution of iNKT-
cell in the protection from EAE. 
 
 
 
 
 
Therapeutical aims for iNKT cells 
 
The control of pathological immune responses causing diseases, such as allergy and 
autoimmunity, has been one of the main goals of immunologists.  
Disease prevention can be achieved by deviating immune responses from a Th2 to 
Th1/Th17 types (or vice-versa) [57]. The induction of lymphocyte populations with 
regulatory capacity, such as Treg or NKT cells, have been also shown to prevent 
immune-mediated diseases [39, 54, 58-60]. Moreover, peripheral tolerance can be 
induced with non-depleting monoclonal antibodies (MAbs), such as the ones targeting 
CD4, CD3 or CD40L [58, 61, 62]. Some of these antibodies were shown to promote 
conversion of non-regulatory T cells into Treg cells in vitro [63]. Interestingly, the 
targets of most tolerogenic MAbs used to generate Treg cells are also shared by iNKT 
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cells – namely CD3, CD4 and CD40L [17]. We therefore hypothesized that the same 
treatment might impact on iNKT cells, thereby affecting the outcome of several 
diseases.  
 
 
Aims of the project 
 
The main objective of this thesis was to study the modulation of iNKT-cell function in 
immune-mediated diseases. 
We first addressed the hypothesis that iNKT cells share with conventional CD4+ T 
cells the plasticity to respond to environmental cues by adopting distinct functional 
phenotypes. We therefore investigated the plasticity of iNKT cells in different in vitro 
systems described to modulate the functional phenotypes of CD4+ T cells, namely by 
inducing polarization to Th17, “Th9” and Treg-like phenotypes. 
Furthermore, we also studied the impact on iNKT cells of immune modulatory 
treatments in disease models in which these lymphocytes have been implicated. In 
particular, we addressed whether an anti-CD4 MAb tolerization protocol in allergy and 
EAE, as well as α-GalCer treatment for the prevention of EAE, would induce changes 
in the iNKT-cell compartment correlating with disease prevention. 
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Materials and Methods 
 
 
Mice 
BALB/c and C57BL/6 (6-8 weeks old) were bred and maintained under specific 
pathogen-free facilities at the Instituto Gulbenkian de Ciência. In each experiment 
animals were sex and age matched. Experiments were performed according to the 
guidelines from the Animal user and Institutional Ethical Comities. 
 
In vivo disease models 
Induction of AAD 
Mice were sensitized with 200 µg of ovalbumin (OVA, grade V; Sigma) intra-
peritoneally (i.n.), previously run on DetoxyGel Column (Pierce) following 
manufacturers instructions, and suspended in 2 mg of endotoxin-free aluminum 
hydroxide (Alu-gel-S, Serv) on days 0 and 14 (Balb/C) or with 100 µg ovalbumin on 
days 0, 7 and 14 (C57BL/6). On days 21 to 23 mice anesthetized with isoflurane were 
intra-nasally (i.n.) challenged with 50 µg of OVA in 50 µl pyrogen-free saline and 
sacrificed 24 hours after the last challenge. On one experimental group mice received 
1mg anti-CD4 MAb i.p. (YTS177, in house production) 1 day before and after each 
sensitization. When indicated, 50 µg HDM house dust mite (HDM, Greer) was used 
instead of OVA during sensitization and challenge. 
Induction of EAE 
Mice were immunized with 200 µg MOG peptide (Boston) emulsified in 200 µg CFA 
solution (4 mg/mL of mycobacteria (Difco) in IFA (Difco)) subcutaneously (100 µg per 
side flank). On the day of immunization and two days after mice received 200 ng 
pertussis toxin in 100 µl PBS intra-venously (i.v.). Disease severity was scored daily on 
a 5 point scale: 1- tail atony; 2- hind limb weakness; 3-hind limb paralysis; 4-
quadriplegia; 5- moribund 
On one experimental group mice received 1mg anti-CD4 MAb, 3 and 2 days prior to 
immunization. On another experimental group mice received 4mg α-GalCer (Alexis 
Biochemicals) in the MOG/CFA emulsion and another 4 mg in PBS i.p. two days later. 
 
Bronchoalveolar Lavage (BAL) 
The trachea was cannulated and the airways were lavaged three times with 1 mL of 
cold PBS1% Bovine Serum Albumine (BSA). The BAL collected was centrifuged at 
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1200 rpm for 5 min, the supernatant was removed and the pellet ressuspended in PBS 
2% fetal bovine serum (FBS) (Invitrogen).  
 
Organ processing 
To remove red blood cells from the lung and CNS, heart was perfused in the right 
ventricle with cold PBS and heparin prior to lung excision. Lungs were cut into thin 
slices and incubated in a shaking orbital incubator at 37ºC for 30 min with collagenase I 
(Sigma, USA) in 10% FBS RPMI 1640 (Invitrogen). CNS was homogeneized, 
incubated for 30 min with colagenase VIII in HBSS, and filtered through 70 µm cell 
strainer. Cell suspension was centrifuged at 1200 rpm for 5 min, the supernatant 
removed and the pellet ressuspended in PBS 2% FBS. The myelin major components 
were further separated from the CNS-cell suspensions in a 30% Percoll (Sigma) 
gradient at 2500 rpm for 20 min at 22ºC.  
Cervical lymph nodes, mediastinal lymph nodes and spleen were collected in PBS 
2% FBS, homogenized and filtered in a 70 µm mesh.  
Spleen, CNS and lung-cell suspensions were depleted of red blood cells with red 
blood cell lysis buffer (8.3 mg/ml NH4Cl, 1 mg/ml KHCO3, and 4 ug/ml EDTA) on ice for 
5 min. The reaction was stopped by the addition of excess PBS centrifuged at 1300 
rpm for 5 min at 4ºC and pellet ressuspended in PBS. 
All Cells were quantified in a Neubauer counting chamber with dead cells exclusion 
by Trypan Blue Solution 0,4 % (Sigma, USA).  
 
Magnetic cell enrichment and cell sorting  
Murine cells were incubated with unconjugated anti-CD16/32 (clone 2.4G2) rat 
antibody (in house production) to block nonspecific binding to FcR and labelled with 
PE-conjugated CD1d-PBS57 tetrameres without washing. Anti-PE magnetic beads 
(Miltenyl Biotech) were added and the magnetically labelled fraction was isolated in an 
autoMACS separator (Miltenyl Biotech). After staining, samples were sorted on a 
FACSAria (Becton Dickinson) with doublet exclusion.  
For human iNKT cell enrichment, cells were labelled with biotinilated anti-CD14 anti-
CD19 and Anti CD123 (clones 61D3, HIB19, 6H6, eBiosciences). Anti-biotin magnetic 
beads were used to deplete the magnetically labelled cells by autoMACS separation.  
 
In vitro cell cultures 
The culture medium was RPMI-1640 with Glutamax, supplemented with 10% FBS, 
1% hepes, 1% penicillin/streptomycin, 1% Sodium pyruvate,  0,1 % β-mercaptoethanol 
(Invitrogen), except for Th17 culture conditions in which it was IMDM with Glutamax  
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5% FBS, 1% penicilin/streptomycin and 0,1% β-mercaptoethanol. Cultures were 
performed at 37ºC 5% CO2.  
For murine Treg conditions, 50,000 FACS-sorted mouse cells were cultured at in 96-
well flat bottomed plates previously coated for 3 hours with anti-CD3 (3 µg/mL, clone 
145-2C11, eBioscience). When required the media was supplemented with TGF-β 
(5ng/mL, R&D Systems) and recombinant IL-2 (5 ng/mL, eBioscience). IL-4 (20 ng/mL) 
was added to CD4+CD25- controls to induce IL-9 secretion. For Th17 polarization 
culture wells were previously coated with anti-CD3 (2µg/mL) and CD28 (5 µg/mL, clone 
37.51, eBioscience). The media was supplemented with TGF-β (1 ng/mL), IL-6 (20 
ng/mL, R&D), IL-1β (10 ng/mL, eBioscience) and anti-INF-γ (10 µg/mL, home made). 
In the end, supernatants were collected and cells stained for flow cytometry. 
For human cell cultures, RPMI was not supplemented with β-mercaptoethanol. 
Lymphocytes from heparinized venous blood samples were isolated by centrifugation 
at 2000 rpm for 30 min on Histopaque 1077 Hybri-Max density gradient (Sigma). 1 
million enriched PBMC lymphocytes were cultured in 24-well flat bottomed plates 
coated with anti-hCD3 (1 µg/mL, clone OKT3, eBioscience). The media was 
supplemented with IL-2 (20U/mL), TGF-β (10 ng/mL) antiCD28 2µg/mL, eBioscience), 
anti-IL12, anti-IL4 and anti-INF-γ (5 ng/mL each). 
 
Flow cytometry 
To prevent unspecific antibody capture by the Fc receptors (FcR), cells were 
incubated with anti-CD16/32 prior to surface and intracellular staining. Cells were 
washed in PBS with 0,01% NaN3, 2 % FBS. Mouse and human CD1d-PBS57 
tetramers coupled to PE were supplied by the NIH Tetramer Facility. Fluorochrome-
labeled monoclonal antibodies against mouse TCRβ APC-Cy-7 (H57-597, 
eBioscience), NK1.1 PE-Cy-7 (PK136, eBioscience), CD25 AlexaFluor488 (PC61, 
produced and conjugated in house), CD25 PE-Cy-7 (PC61.5, eBioscience), CD4 
PerCp-Cy5.5 (RM4-5, eBioscience), CD3 PerCp-Cy5.5 (145-2C11, Biolegend), CD62L-
APC (MEL-14, eBioscience), CD103-Biotin (2E7, eBioscience), Streptavidin PerCp-
Cy5.5 (eBioscience),  MAC1 AlexaFluor488 (CD11b, produced and conjugated in 
house),  Streptavidin PE-Cy-7 (eBioscience). For intracellular staining, cells were fixed 
and permeabilized using Foxp3 Staining Set (eBiosciences) and then stained for 
cytokines and Foxp3-APC (FJK-16s, eBioscience). For intracellular cytokine detection 
freshly collected lymphocytes were first incubated with 50ng/mL 4-α-phorbol-12-
mystrate-13-acetate (PMA) and 500ng/mL ionomycin (Sigma) in culture media. 1 hour 
later Brefeldin A (Sigma) was added at final concentration of 10 µg/mL and incubation 
allowed for another 2h. Cells were then treated as previously described, and stained for 
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intracellular cytokines with: IL-17 PE (17B7, eBioscience) and IL-9-PE (RM9A4, 
Biolegend). 
Six colours acquisition was performed using a FACSCanto (BD Bioscience) with dual 
laser excitation (488nm and 633nm) using FACSDiva Software. The analysis gate was 
set on forward and side scatters to exclude dead cells, cell debris and granulocytes 
using FlowJo6.4.2 (Treestar). Absolute cell numbers were determined by multiplying 
the frequency of each population within the analysis gate with the cells counted by 
microscopy (as mentioned).  
 
Immunoglobulin and cytokine detection 
OVA specific IgG1 and IgE levels in the serum were quantified by ELISA performed 
using IgG1 kit (SouthernBiotech) with IgG1 anti-OVA standard (Serotec) and IgE 
Opteia kit (BD Pharmingen). The quantification of cytokines in the cell-culture 
supernatant or in the lung homogenates was performed using IL-10, IL-13, IFN-γ kits 
(Prepotech, London, UK); IL-4, IL-5 Opteia kits (BD Pharmingen) or IL-17 kit (R&D 
Systems). Detection of IL-9 was performed using the cytokine bead-array Mouse IL-9 
Flex Set (BD Pharmingen). All assays were performed according to the manufacturer’s 
instructions. 
 
Statistical analysis 
Statistical significance was determined using a two tailed non-parametric Student’s t 
tests (Mann-Whitney) with Prism 4.0 (GraphPad Prism 5). Significant differences were 
considered when p<0,05 (*, P<0,05; **, P<0,01; ***, P<0,001) 
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Results 
 
 
NK1.1/CD4 iNKT-cell subpopulations induce de novo 
expression of Foxp3 and IL-9 upon activation in the presence of 
TGF-β 
 
The host group has been studying the plasticity of iNKT cells when activated in the 
presence of TGF-β. We have shown for the first time that, like T lymphocytes, both 
murine (Fig. 2A) and human iNKT (Fig. 2C) lymphocytes are able to convert to Foxp3 
when activated in the presence of IL-2 and TGF-β. It should be noted that these cells 
retain defined murine NKT-cell markers, namely the specific transcription factor PLZF 
(unpublished data by M. Monteiro). Moreover, in mice, expression of Foxp3 was not 
restricted to CD4+ but also found within the CD4- iNKT-cell subset (Fig. 2A) being 
Foxp3+ iNKT cells exclusively NK1.1- (Fig. 2B). This led us to hypothesize whether only 
NK1.1- iNKT cells can be converted towards Foxp3 expression or whether this 
phenotype reflects a different functional state of iNKT cells. 
 
Fig. 2 iNKT cells can induce Foxp3 expression in vitro. (A) Murine iNKT cells were 
isolated from the spleen of C57BL/6 mice, enriched for iNKT cells and FACS-sorted as 
CD1d/PBS57+TCRb+ cells. CD4+CD25- lymphocytes were sorted as controls. Both cell types 
were cultured in the presence of TGF-β and IL-2 and activated with plate bound anti-CD3 (A, 
B). (A) Intracellular Foxp3 expression was analyzed 3 days later by flow cytometry. (B) Murine 
Foxp3+ iNKT cells were CD4+ or CD4- and NK1.1-. (C) Human PBMCs were isolated and 
cultured in the presence of TGF-β and IL-2, as well as in the presence of anti-CD28, IL-4, anti-
IL-12 and anti-IFN-γ mAbs. Cultures were analyzed 5 days later. iNKT cells were identified as 
CD1d/PBS57+Vβ11+ cells, and Foxp3 expression assessed by intracellular FACS staining. 
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To address this question splenic iNKT cells from C57Bl/6 mice were enriched for 
iNKT cells and FACS-sorted according to the expression of NK1.1 and CD4: 
CD4+NK1.1-; CD4+NK1.1+; CD4-NK1.1+ CD4-NK1.1-. CD4+CD25- T cells from the 
negative fraction were used as controls (Fig. 3)  
 
Fig. 3 Sorting strategy of NK1.1/CD4 iNKT-cell subpopulations. (A) iNKT cells from 
C57BL/6 mice were isolated from the spleen, enriched for iNKT cells and identified after gating 
on the live population, followed by doublet exclusion as CD1d/PBS57+TCRb+ cells. (B) 
NK1.1/CD4 iNKT subpopulations were FACS-sorted (C) CD4+CD25- lymphocytes were sorted 
as controls. 
 
 
The sorted populations were stimulated for 3 days in the presence of IL-2 and TGF-β, 
a condition known to drive the up-regulation of Foxp3. Although Foxp3 was not 
detected by flow cytometry in freshly isolated splenic iNKT cells (Fig. 4 A), we showed 
that all subpopulations were able to induce de novo expression of Foxp3. The highest 
frequency of Foxp3+ cells was found in NK1.1- CD4- cell cultures (~40%), whereas the 
remaining subsets showed conversion rates around 20% (Fig. 4 B and C).  
We also observed that, although we could not detect intracellular expression of IL-9 
ex vivo in total iNKT cells isolated from naïve animals (Fig. 4A), these were able to 
induce IL-9 expression when activated in vitro in the presence of TGF-β, as described 
for conventional CD4+ T cells [6, 7] (Fig. 4D). Like iNKT lymphocytes that have up-
regulated Foxp3, IL-9+ iNKT cells were all NK1.1- (Fig. 4D). 
 When the different NK1.1/CD4 iNKT-cell subpopulations sorted by flow cytometry, 
but not CD4+CD25- T-cell controls, were isolated prior to culture and stimulated in the 
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presence of TGF-β and IL-2, the expression of IL-9 was detected among Foxp3- cells 
of all subpopulations (Fig. 4E). 
IL-9 expression was assessed by intracellular staining of iNKT cells (Fig. 4B and E). 
NK1.1+CD4- and NK1.1+CD4+ iNKT cells induced IL-9 expression in 7-15 % of the cells 
after 3 days of culture, twice as much as their NK1.1- counterparts. In CD4+CD25- T 
cells, however, IL-9 expression was only induced when exogenous IL-4 was added to 
cultures.  
IL-4 has been described as essential for “Th9” conversion [6, 7]. Despite exogenous 
IL-4 was not added to the cultures, it is well established that iNKT cells respond to 
stimulation by secreting high amounts of IL-4 [26]. We hypothesized that iNKT-cell 
activation by the plate-bound anti-CD3 in our culture system was driving IL-4 secretion 
by iNKT cells. This cytokine, acting on iNKT cells in an autocrine way and synergizing 
with TGF-β, would therefore induce IL-9 expression, thus overcoming the requirement 
for exogenous addition of IL-4. 
In fact, IL-4 was detected in culture supernatants at similar levels within all sorted 
iNKT-cell sorted populations, but not in CD4+ CD25- T-cell controls (Fig. 4F). This 
indicates that all NK1.1/CD4 iNKT-cell subpopulations were able to produce IL-4 
following activation, independently of the presence of TGF-β. 
In a subsequent experiment, we observed that neutralization of IL-4 in the cultures, 
with an anti-IL-4 antibody, resulted in a reduction of IL-9 release to the supernatant in a 
dose dependent manner, without affecting Foxp3 expression (Fig. 4G). 
Collectively, these results show that IL-9 can be produced by all NK1.1/CD4 iNKT 
subpopulations, being dependent on TGF- β and IL-4. 
In addition, our results indicate that cells converting to Foxp3 or IL-9 down-regulated 
NK1.1 and, in some cases, also CD4 expression. Importantly, cells that did not convert 
or that were activated in the absence of TGF- β showed the same tendency to loose 
NK1.1 and/or CD4 expression (Fig. 4H and data not shown). 
These results demonstrate that all NK1.1/CD4 subpopulations of iNKT cells can be 
converted towards de novo expression of Foxp3 and IL-9 when cultured in the 
presence of TGF- β and IL-2, becoming NK1.1- after conversion 
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Fig. 4 Different NK1.1/CD4 iNKT cells are susceptible to Foxp3 and “Th9” 
polarization in vitro in the presence of TGF-β and IL-2. (A) iNKT cells freshly isolated 
from the spleen of C57BL/6 mice were stimulated with PMA/ionomycin for 3 hours and Foxp3 
and IL9 expression was assessed by flow cytometry (isotype controls are also depicted): Foxp3 
and IL9 were not detected in freshly isolated iNKT cells T cells expression. 50,000 cells of 
FACS-sorted NK1.1/CD4 iNKT subpopulations activated with plate-bound anti-CD3 in the 
presence of IL-2 and TGF-β. In some conditions, cells were deprived of TGF-β. After 3 days, 
cells were further stimulated for 3 hours in the presence of PMA/ionomycin and flow cytometric 
detection of Foxp3 and IL-9 was performed (B,C,D,G). (B) Representative dot plots are 
presented for the different FACS-sorted subpopulations. (C) Bar graphs depict the average 
frequency in culture triplicates of cells that have induced Foxp3, being the maximum achieved 
by NK1.1-CD4- subpopulation. (D) iNKT cells activated in presence of TGF-β can express IL-9, 
and IL-9+ cells are NK1.1- CD4+ or CD4-. (E) At the end point the supernatants were collected 
and IL-4 secretion detected by ELISA in FACS-sorted iNKT-cell subpopulations. (F) The 
addition of increasing doses of anti-IL4 antibody reduced IL-9 detection by CBA in the 
supernatants without affecting Foxp3 expression. (G) NK1.1 and/or CD4 expression of Foxp3+ 
(or IL9+, not shown) cells was downmodulated at the end of the cultures. 
 
 
 
 
NK1.1/CD4 iNKT-cell subpopulations express IL-17 in the 
presence of IL-6, IL-1β, anti-IFN-γ and TGF-β 
 
IL-17 production by iNKT cells was ascribed to a fixed lineage: the NK1.1- [32] or 
NK1.1-CD4- [31] subpopulations. Our observations that different NK1.1/CD4 splenic 
iNKT-cell subpopulations can convert to IL-9 or Foxp3, downmodulating NK1.1 and/or 
CD4, prompted us to hypothesize that different subsets of iNKT cells can be polarized 
towards IL-17 production, acquiring a NK1.1- phenotype as they acquire this new 
functional state. 
Although we could not detect IL-17 expression in freshly isolated iNKT-cells from 
spleen of naïve mice (the existing reports agree that in naïve mice IL-17+ iNKT cells are 
a minute population), IL-17 became detectable after cells were cultured under the 
conditions described to convert conventional CD4+ T cells to Th17 [16] (Fig. 5A). 
Importantly, most IL-17 producers became NK1.1-, which again raised the question 
whether IL-17 could only be produced by NK1.1- iNKT-cells, or this reflects 
differentiation state of iNKT-cells. 
We therefore isolated by flow cytometry the four NK1.1/CD4 iNKT cell subsets to 
assess their capacity to undergo Th17-like differentiation After 4 days, all NK1.1/CD4 
subpopulations cultured in presence of TGF-β, IL-6, IL-1β and anti-IFN-γ induced IL-17 
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expression (Fig. 5B). Maximum IL-17 expression was found within NK1.1-CD4- 
subpopulation, in which 23-30% of the cells upregulated IL-17. In the other 
subpopulations conversion rates were below 10% (Fig. 5B and C). ELISA 
measurements of IL-17 in culture supernatants confirmed that NK1.1- subpopulations 
secreted significant higher amounts of IL-17 than their counterparts and CD4+25- T cell 
controls (Fig. 5D). In addition, we observed that in all cultured subpopulations, the cells 
expressing IL-17 had downmodulated NK1.1 and/or CD4 (Fig. 5E). 
In conclusion, our results show that all NK1.1/CD4 iNKT subsets are capable of induce 
de novo expression of IL-17, although with different efficiencies, thus disaccording with 
previous reports suggesting that IL-17 production by iNKT cells was restricted to 
NK1.1- subpopulations.  
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Fig. 5 Different NK1.1/CD4 iNKT cells express IL-17 in the presence of IL-1β IL-6 
anti-IFN-γ and TGF-β. (A) iNKT cells freshly isolated from the spleen of C57BL/6 mice were 
stimulated with PMA/ionomycin for 3 hours and IL-17 expression accessed by flow cytometry. 
IL-17 was not detected in iNKT cells ex-vivo but only when cultured in Th17 polarizing 
conditions. Polarized cells were NK1.1-CD4+ or NK1.1-CD4-. 50,000 cells of each FACS-sorted 
NK1.1/CD4 iNKT subpopulations were activated with plate-bound anti-CD3 and anti-CD28 in 
the presence of IL-1β, IL-6, anti-IFN-γ and TGF-β. Controls were deprived of TGF-β. After 5 
days, cells were further stimulated for 3 hours in the presence of PMA/ionomycin (B,C,E). (B) 
IL-17 intracellular expression expression was detected by flow cytometry in different cultured 
subpopulations (C) Average frequency in culture triplicates of cells expressing IL-17 after 
culture. (D) IL-17 secretion in the culture supernatants was assessed by ELISA (non-continuous 
line depicts top standard curve; values represent concentrations normalized to the number of 
cells/well) (D). (E) NK1.1 and/or CD4 expression of Th17+ cells were downmodulated at the end 
of the cultures. 
 
 
 
Co-receptor blockade with non-depleting anti-CD4 prevented 
allergic sensitization in BALB/c mice 
 
Data previously obtained by the host group indicate that a non-depleting anti-CD4 
monoclonal antibody (MAb) can prevent allergic sensitization in a well established 
murine model of allergic airways disease (AAD), leading to allergen-specific tolerance 
(unpublished data by A. Agua-Doce). Animals tolerized with CD4 MAb were protected 
from allergic manifestations elicited by allergen exposure: they did not develop airways 
eosinophilia; the production of Th2 cytokines in the lung was markedly reduced, without 
Th1 deviation being observed; the production of allergen-specific IgE or IgG1 was 
abrogated; and, more importantly, no AHR was elicited in response to increased doses 
of inhaled methacholine (MCh) (unpublished data by A. Agua-Doce – Annexes - 
Supplemental Fig. 1). 
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As iNKT were shown to be important for induction of AAD, and as these cells can 
also express CD4, we investigated whether tolerance induced by CD4 blockade might 
also impact on the iNKT-cell compartment.  
 
 
Co-receptor blockade with non-depleting anti-CD4 in AAD 
reduced iNKT cell infiltrates in BAL and lung and altered the 
phenotype of iNKT cells in the medLNs 
 
Female BALB/c mice were sensitized with ovalbumin (OVA)-alum on days 1 and 14 
and challenged intranasally with OVA on days 20, 21 and 22 (Fig. 6A).  Experimental 
animals were treated with anti-CD4 at the time of sensitization. Bronchoalveolar lavage 
(BAL), lungs, mediastinal draining lymph nodes (medLNs), spleen and blood serum 
were collected 24 hours after the last OVA challenge and analyzed by flow cytometry.  
 
 
iNKT cells were identified using CD1d/PBS57-labelled tetramers after CD11b, dead 
cells and doublet exclusion (Fig. 6B). Allergic animals exhibited an increase in the 
frequency and absolute number of iNKT cells in the lungs, BAL but not in medLNs 
(where only the number was increased) when compared to healthy controls (Fig. 6C 
and D). Moreover, 60-80% of the infiltrating iNKT cells in the lungs and BAL expressed 
the CD4 co-receptor, thus supporting the possibility of direct targeting by anti-CD4 MAb 
(Fig. 6E). 
Mice tolerized with anti-CD4 MAb showed a significant reduction in iNKT-cell 
infiltrates in lungs and BAL, but not in medLNs or spleen (Fig. 5C and D), when 
compared to allergic animals. Although medLNs from anti-CD4 treated mice contained 
similar numbers of iNKT cells as AAD controls, we observed changes in the phenotype 
of iNKT cells: there was a marked reduction of CD103+ and CD62L+ iNKT cells from 
treated animals (Fig. 6E). Moreover, the antibody was able to reduce CD4+-expressing 
iNKT cells in lungs, BAL and medLNs without leading to direct lysis of CD4+ iNKT cells 
(or CD4+ T cells), as these populations in the spleen remained unchanged. This 
observation was not due to receptor occupancy by the MAb, as our in vitro studies 
showed that the antibody used in flow cytometry is able to bind CD4 on the cell surface 
even in the presence of the therapeutic MAb (data not shown). 
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Using HDM, a more physiologic allergen than OVA, to induce AAD, we also observed 
that not only eosinophils and lymphocyte were increased in the airways of allergic 
animals, but iNKT-cell infiltrates were increased as well. Notably, cell numbers were 
restored to basal levels after the same tolerogenic treatment with anti-CD4 MAb (Fig. 6 
F). 
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Fig. 6 Non-depleting anti-CD4 MAb tolerization to AAD correlates with a 
reduction in iNKT-cell infiltrates in the airways and alteration of phenotype in the 
draining LNs. (A) iNKT cells were detected by FACS according to the co-expression of TCRβ 
and CD1d /PBS57 tetramers, after exclusion of dead cells, doublets and CD11b expressing 
cells. Control staining with unloaded tetramer is also depicted. (B) Representative dot plots of 
iNKT-cell identification in the BAL, lungs and medLNs: untreated mice showed an increased 
percentage of iNKT cells, which was reduced after anti-CD4 MAb treatment (C). Absolute cell 
counts of infiltrating iNKT cells in medLNs, lungs, and more significantly BAL were increased in 
allergic when compared to healthy controls. Mice treated with anti-CD4 MAb showed a 
significant reduction of iNKT cells in the BAL and lungs but not in the mediastinal LNs or spleen. 
(D) Mean Fluorescense intensity (MFI) of CD4 and CD103 and frequency of CD62L (Non filled 
lines represent the naïve group, black filled the OVA, and grey filled the treated group. Black 
grey and italic numbers represented in graphs indicate the frequency of CD4+ iNKT cells in 
medLNs): anti-CD4 tolerization protocol reduced the expression of CD4, CD103 and CD62L. (E) 
In a similar protocol using HDM instead of OVA as an allergen, the anti-CD4 MAb treatment was 
able to reduce eosinophilic, lymphocytic and monocytic accumulation in the BAL as well as the 
iNKT-cell numbers. 
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Co-receptor blockade with non-depleting anti-CD4 prevented 
EAE and led to an increase of Foxp3+ iNKT cells  
 
Some groups have provided convincing evidence that iNKT cell content is inversely 
correlated with EAE manifestations, thus supporting the idea that iNKT cell play a 
beneficial role in this disease [54, 55].  
Since we have discovered that this unconventional lymphocyte population has the 
ability to express Foxp3, we addressed the possibility of Foxp3 being up-regulated by 
iNKT cells in EAE. For that we used a relapsing-remitting EAE model in C57BL/6 mice, 
already established in our lab by J. Duarte, to study the effect of anti-CD4 tolerization 
protocol. Briefly, mice were immunized with MOG/CFA emulsion, with pertussis toxin 
administered on the day of immunization and two days later. In one experimental 
group, mice received 1 mg of anti-CD4 MAb 3 and 2 days prior to immunization (Fig. 
7A). Disease manifestations were followed daily and individually mice scored according 
to severity of the clinical manifestations (Fig. 7B). 
Mice were sacrificed when the majority was at the first peak of the disease (score 4), 
and before the recovery phase. Cervical lymph nodes (cervLNs), CNS and spleen were 
collected and analyzed. Our data show that anti-CD4-MAb administration was able to 
prevent MOG-induced progression of EAE, as animals treated with anti-CD4 exhibited 
no symptoms of the disease, in contrast to mice that did not receive the treatment (Fig. 
6B). Furthermore, lymphocyte infiltrates in the CNS, characteristic of EAE pathology, 
were not observed in mice that had received anti-CD4 MAb (Fig. 7C), and iNKT-cell 
counts and frequency in the CNS, cervLNs and spleen were restored to healthy control 
levels (Fig. 7D and E ). 
Of note, we detected, for the first time, Foxp3 expressing-iNKT cells in the cervLNs, 
but not in spleen, of sick and treated mice (Fig. 7F). Interestingly this subset increased 
in frequency and absolute numbers in the anti-CD4 treated group (Fig. 7G). 
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Fig. 7 Prevention of EAE following non-depleting anti-CD4 MAb treatment 
correlates with an increase of Foxp3+ iNKT cells. (A) Experimental model: C57BL/6 
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mice were sensitized with MOG peptide. On one experimental group mice received 1mg 
antiCD4 Mab 3 and 2 days prior to immunization. (B) Average clinical scores of mice immunized 
with MOG in the presence or absence of antiCD4: mice that received anti-CD4 did not elicit 
EAE manifestations. Disease severity was scored daily on a 5 point scale: 1- tail atony; 2- hind 
limb weakness; 3-hind limb paralysis; 4-quadriplegia; 5- moribund (C) Anti-CD4 administration 
before MOG immunization was able to reduce total lymphocyte infiltrates in the CNS when 
compared to mice that were not tolerized (D) Immunized mice presented iNKT infiltrates in the 
CNS, and lower iNKT cell numbers in the spleen and cervLNs, when compared to healthy 
controls. Mice treated with anti-CD4 MAb prevented this effect. (E) Representative dot plots of 
iNKT-cell identification in the cervLNs: MOG immunized animals showed decreased percentage 
of iNKT cells upon treatment Foxp3 was detected by flow cytometry in the cervLNs of 
immunized mice, but not in naïve animals. Anti-CD4 MAb led to an increase in the percentage 
of Foxp3+ iNKT population (representative dot plots). (F) Total numbers of the Foxp3+ iNKT 
cells are increased in tolerized animals.  
 
 
 
α-GalCer administration prevented EAE and led to an increase 
in Foxp3+ iNKT cells  
 
It was shown that in vivo activation of iNKT cells with the specific ligand α-GalCer 
ameliorates EAE by preventing Th17 differentiation of auto-reactive T cells [39, 55]. To 
test whether iNKT activation, in this disease model, correlates to the increase in the 
numbers of Foxp3+ iNKT cells, we established a new experimental group where mice 
received α-GalCer – a specific ligand of iNKT cells – on the day of MOG immunization 
and 4 days later, in accordance to a protocol described elsewhere [56] (Fig. 8A). We 
observed that animals treated with α-GalCer did not develop clinical manifestations of 
the disease (Fig. 8B), nor display lymphocyte infiltrates in the CNS (Fig. 8C). 
Additionally, iNKT-cell frequency and total numbers were increased in the spleen and 
cervLNs (Fig. 8D and E), as well as the number of Foxp3+ iNKT cells detected in the 
cervLNs, when comparing to sick animals (Fig. 8F and G). 
These data suggest that strategies effective in preventing EAE correlate with the 
emergence of Foxp3+ iNKT cells in CNS-draining cervLNs. 
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Fig. 8 Prevention of EAE by α-GalCer treatment correlates with increased 
Foxp3+ iNKT cells. (A) Mice were immunized with MOG as described in figure 7. One 
experimental group received 4 µg of α-GalCer, in the MOG/CFA emulsion, and another 4 µg 4 
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days later i.p. (B) Average of the clinical scores of mice immunized with MOG in the presence or 
absence of α-GalCer: mice in which iNKT cells were activated with α-GalCer did not elicit EAE 
clinical manifestations. (C) α-Galcer activation of iNKT cells along with MOG immunization was 
able to reduce total lymphocyte infiltrates in the CNS when compared to mice that did not 
receive α-GalCer treatment. (D) The numbers of iNKT cells in the cervLNs and spleen of mice 
receiving α-GalCer were restored to healthy control levels. (E) Representative dot plots of iNKT-
cell identification in the cervLNs: the percentage of iNKT cells was restored to healthy control 
levels in the group that has received α-Galcer along with immunization. (F) Foxp3 expression 
was detected by flow cytometry in the cervLNs: activation of iNKT cells with α-GalCer led to an 
increase in the percentage of Foxp3+ iNKT population (representative dot plots). (G) Total 
numbers of the Foxp3+ iNKT cells were also increased in the group receiving α-GalCer. 
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Discussion 
 
 
Many groups have studied the capacity of iNKT cells to mimic different Th subtypes. 
Overall, it is accepted that different lineages tend to express distinct phenotypes. For 
instance CD4+ iNKT cells have been described to acquire Th2-like phenotypes, while 
CD4- iNKT present Th1-like phenotypes [20, 26, 64]. More recently, a Th17-like 
phenotype was considered  to be restricted to NK1.1-CD4- subpopulations  [31, 32]. In 
addition it has been suggested that different NKT cell ligands can preferentially 
stimulate Th2-like or Th1-like cytokine production). 
We showed that different NK1.1/CD4 iNKT-cell subpopulations can be induced to 
express Foxp3 and IL-9 de novo following in vitro activation in the presence of 
exogenous TGF-β and IL-2. Although, “Th9” conversion requires the simultaneous 
presence of TGF-β and IL-4 [6, 7], we demonstrated that iNKT cells do not require the 
addition of exogenous IL-4 to induce IL-9 expression. This is due to the presence in the 
cultures of IL-4 secreted by the different NK1.1/CD4 iNKT-cell subpopulations upon 
activation that, in synergy with the exogenous TGF-β, is sufficient to induce de novo IL-
9 expression. 
iNKT-cells producing IL-17 were described as being a fixed lineage found within 
NK1.1-CD4- compartment [31, 32]. However we observed that IL-17 expression could 
be induced in all NK1.1/CD4 iNKT-cell subpopulations after culture under Th17 
conditions. Although our data is not sufficient to exclude expansion from pre-existing 
precursors, because IL-17 was detected in cultured NK1.1-CD4+ cells without the 
addition of TGF-β, we showed that IL-17 expression by iNKT cells is not restricted to 
the NK1.1-CD4- subpopulation, thus strongly suggesting that besides a possible 
expansion some iNKT cells can be converted towards IL-17 production. This 
challenges the general assumption that IL-17 secretion is restricted to NK1.1-CD4- 
iNKT-cell subset.  
We also observed that upon Foxp3, IL-9 or IL-17 up-regulation most iNKT cells lose 
NK1.1 and/or CD4 expression. Interestingly, downmodulation of NK1.1 and/or CD4 
was previously described as a strategy to avoid overstimulation  [7]. The fact that all 
NK1.1/CD4 iNKT-cell subsets downmodulate NK1.1, and sometimes CD4, while 
acquiring Foxp3, IL-9 or IL-17 expression, rather supports the idea that the NK1.1-CD4- 
phenotype of IL-17-producing iNKT cells reflects a functional state rather than a 
specific lineage.  
Note that the amount of IL-17 (and IL-9, not shown) secreted by iNKT-cell 
subpopulations to the culture supernatant was significantly higher than those achieved 
   39/48 
by CD4+ conventional T cells, which suggests an important biological relevance for 
these cells. 
Collectively, our data demonstrates that iNKT cells, independently of their NK1.1/CD4 
phenotype, can behave differently and activate different differentiation programs when 
exposed to distinct environments. 
To investigate the possibility of modulate iNKT cells in vivo we studied iNKT cells in 
disease models in which iNKT cells have been shown to be implicated, allowing them 
to behave more physiologically. 
Taking advantage of a well established allergic airways disease model in which iNKT 
cells were described to play an aggressive role [35, 45, 65], we evaluated the impact 
on iNKT cells of a non depleting anti-CD4 MAb tolerogenic treatment known to prevent 
AAD. Our results confirmed that AAD correlates with increased iNKT-cell content, both 
in terms of frequency and cell numbers, in lung and BAL, and a decrease in medLNs. 
Notably, anti-CD4 MAb treatment reduced to basal levels the numbers of iNKT cells in 
the lungs and BAL. Although the number in the medLNs was not significantly affected 
with the treatment, we observed phenotypic changes that might correlate with the 
outcome: CD62L expression was increased, and CD103 and CD4 expressions 
decreased.  
Using HDM, a clinically relevant allergen, similar results where obtained: iNKT-cell 
infiltrates in the airways are increased in allergic animals and could be restored to 
basal levels after the anti-CD4 tolerogenic treatment. Models with HDM might be of 
more relevance to study the role of iNKT-cells in asthma due to the existence of 
glycolipids in the HDM that might be directly recognized by iNKT cells. 
Our results clearly show that anti-CD4 treatment is able to prevent AAD, not only by 
targeting conventional CD4 T cells, but also through modulation of iNKT lymphocytes. 
A better characterization of the cytokines and transcription factors expressed by iNKT 
cells from allergic and tolerant mice would be important to help understanding the 
mechanism by which iNKT cell phenotype and function correlates with the outcome. 
For instance, it would be interesting to investigate whether iNKT cells would contribute 
to mast cell activation in asthma by producing IL-9[66]. The use of adoptive transfer 
strategies or transgenic mice lacking iNKT or CD4 T cells will be helpful to clarify these 
issues, and will allow an investigation on how tolerogenic protocols can prevent the 
disease by controlling pathogenic iNKT cells. 
In the context of EAE, iNKT cells were shown to correlate with the remission from the 
disease which suggests they might play a beneficial role [39]. In a MOG-induced EAE 
model we confirmed iNKT cells were decreased in affected animals, although being 
detectable in the CNS infiltrates. Importantly, mice that received anti-CD4 treatment 
exhibited iNKT-cell numbers similar to naïve controls and were protected from the 
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disease. Since the results obtained with iNKT-cell cultures indicated these cells can up-
regulate Foxp3 expression, we investigated if protection of EAE conferred by anti-CD4 
MAb treatment correlated with Foxp3 induction in iNKT cells. Importantly, we were able 
to detect, for the first time, Foxp3+ iNKT cells in the cervLNs, but not in the spleen, of 
immunized mice. This subset was detected in sick mice and significantly upon anti-CD4 
or α-GalCer treatments. In fact, previous studies in transplantation correlated de novo 
generation of Foxp3 Treg lymphocytes in a TGF-β-dependent process with tolerance 
induced by anti-CD4 co-stimulation blockade [63, 67]. However, results did not indicate 
that tolerance elicited by anti-CD4 MAb treatment to MOG induced EAE induces Foxp3 
up-regulation by conventional CD4+T cells (data not shown). Nevertheless, 
Foxp3+iNKT-cell numbers were increased in anti-CD4 MAb treated mice, suggesting 
that CD4 blockade is either favoring Foxp3 up-regulation by iNKT lymphocytes or, 
alternatively promoting their expansion. Interestingly we observed that the 
administration of α-GalCer to MOG sensitized mice was also able to prevent clinical 
manifestations of the disease, correlating to increased numbers of Foxp3+ iNKT cells. 
Activation of  iNKT cells was already reported to ameliorate EAE by preventing Th17 
differentiation of auto reactive T cells [56]. However the expression of Foxp3 by iNKT 
cells had never been investigated in vivo. Further studies are required to clarify how 
anti-CD4 MAb treatment and α-GalCer activation contribute to Foxp3+ iNKT-cell 
increase and to understand how this correlates with disease prevention. 
As illustrated by our in vitro studies, TGF-β is absolutely essential for Foxp3 up-
regulation by iNKT cells. We now aim to address if TGF-β is also required for the 
induction of Foxp3+ iNKT cells in vivo by administrating the above-described tolerating 
strategies to dominant negative TGF-βRII mice, a strain in which T and NKT cells are 
unable to transduce TGF-β signals, which have been induced with EAE.  
 
Finally, although Foxp3 is not easily detectable by flow cytometry in iNKT cells in 
most organs of mice, such possibility should not be excluded since the TCR of iNKT 
cells is rapidly internalized upon activation, becoming difficult to identify them. 
Moreover, Foxp3+ iNKT cells are probably a reduced population that expands in cases 
of disease. Therefore new strategies to identify iNKT-cells, such as PLZF antibodies or 
even PLZF-GFP transgenic mice, are urgently required to investigate the physiological 
relevance of Foxp3+ iNKT cells as well as other iNKT cell subsets. 
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Concluding remarks and Future perspectives 
 
 
Our results show that iNKT cells can induce Foxp3, IL-9, and IL-17 expression. 
Moreover, these cells are able to polarize into Foxp3, “Th9” and Th17- like phenotypes, 
when exposed to different environments, independently on NK1.1/CD4 expression, 
which reveals a high degree of plasticity instead of a previous considered lineage 
commitment. We also demonstrated that anti-CD4 MAb treatment is able to prevent 
AAD and impact on iNKT cells, by reducing their number in BAL and lung, and 
changing their phenotype in medLNs. Additionally, anti-CD4 MAb treatment and α-
GalCer-mediated activation is able to prevent EAE and promoting the increase of 
Foxp3+ iNKT cells. 
Overall, these data suggest that modulation of iNKT cells can be a useful therapeutic 
strategy to induce functional specialization and to prevent disease, thus widening the 
prospect of autologous cell therapy.  
We intend to further study the ability of human iNKT cells to stably polarize to 
different Th subtypes (Th17, “Th9”, Foxp3), optimize their expansion and perform 
functional assays in order to establish iNKT-cell-based therapies. In fact, our 
preliminary data confirms that iNKT cell from human peripheral blood can be expanded 
in vitro in response to α-GalCer (data not shown),  
Finally, we aim to clarify the implication of human iNKT cells in asthma and test 
whether the severity of disease can correlate to iNKT cell content and/or phenotype. 
For that, we have established a protocol with the Chest Medicine Unit of Hospital de 
Santa Maria giving us access to samples of induced sputum from asthmatic patients. 
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Annexes 
 
 
 
 
Supplemental Fig. 1 Administration of non depleting anti-CD4 MAb 
prevents AAD in mice. (A) Experimental model: female BALB/c mice were sensitized with 
20 µg OVA-alum i.p. and challenged with 50 µg OVA in saline intranasal on the indicated days. 
Experimental groups were treated i.p. with 1 mg of anti-CD4 non-depleting MAb or isotype 
control. (B) Invasive measurements of respiratory mechanics: animals treated with anti-CD4 
MAb had reduced airway resistance, tissue elastance and tissue damping in response to 
increasing doses of inhaled methacholine (MCh), when compared to sensitized animals (n=8, 
P<0.01 for [MCh] ≥10 mg/ml) (C) Cellular composition of the BAL: mice treated with anti-CD4 
show 100 fold less eosinophils and lymphocytes in the BAL. (D) Anti-CD4 MAb-treated mice 
showed a significant reduction in allergen-specific Th2-driven immunoglobulins measured by 
ELISA. (E) The Th2 cytokines IL-13, IL-4, and also IL-5 were down to basal levels in lung 
homogenates from anti-CD4 MAb-treated mice, without an increase in IL10, IFN-γ or TNF 
levels. 
 
